Barclays’s Co-Diagnostics CODX Stock Holding History

Barclays’s Portfolio CODX Stock Details CODX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-216	Closed	-$36K	–	4830
2022 Q2	$36K	Hold	216	–	–	﹤0.01%	4168
2022 Q1	$40K	Hold	216	–	–	﹤0.01%	4199
2021 Q4	$58K	Sell	216 -186	-46%	-$48.8K	﹤0.01%	3820
2021 Q3	$117K	Sell	402 -794	-66%	-$232K	﹤0.01%	3845
2021 Q2	$296K	Sell	1,196 -258	-18%	-$66.3K	﹤0.01%	3357
2021 Q1	$416K	Sell	1,454 -3,162	-69%	-$1.26M	﹤0.01%	3285
2020 Q4	$1.29M	Sell	4,616 -119	-3%	-$44.1K	﹤0.01%	2581
2020 Q3	$1.93M	Sell	4,735 -71	-1%	-$36.5K	﹤0.01%	2133
2020 Q2	$2.79M	Buy	+4,806	New	+$2.19M	﹤0.01%	1818
2020 Q1	–	Sell	-2,892	Closed	-$78K	–	6171
2019 Q4	$78K	Buy	2,892 +460	+19%	+$13.6K	﹤0.01%	5587
2019 Q3	$75K	Buy	2,432 +1,815	+294%	+$60.3K	﹤0.01%	5687
2019 Q2	$15K	Buy	+617	New	+$17.3K	﹤0.01%	6472

Other funds holding CODX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Barclays's CODX Position: Q3 2022 in Review

Barclays sold out of Co-Diagnostics (CODX) in Q3 2022, closing a stake of 216 shares — an estimated $36K sold.

Barclays first reported a position in CODX in Q2 2019 and held it in 12 quarters. The position peaked at $2.79M in Q2 2020. 65 funds tracked by Wall St. Rank hold CODX as of Q3 2022.

Barclays reported no remaining Co-Diagnostics position as of Q3 2022 after selling out during the quarter.
Barclays sold 216 Co-Diagnostics shares in Q3 2022, an estimated $36K.
Barclays first reported a position in Co-Diagnostics in Q2 2019 and held it in 12 quarters.
Barclays's Co-Diagnostics position peaked at $2.79M in Q2 2020.
65 funds tracked by Wall St. Rank held Co-Diagnostics as of Q3 2022.

Based on Barclays's 13F filing for Q3 2022, filed 3 Nov 2022.